patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

setmelanotide

Marketedupdated 2mo ago

by $RYTM RHYTHM PHARMACEUTICALS, INC.

Approved

community read0 votes

Protein drug with a maximum clinical stage of Approval, with an approval for obesity.

indications

investigational

Obesity

all catalysts(6)

approval · 6

News(0)

no news has mentioned this drug yet

brand

Imcivree

generic

setmelanotide

MOA

12.1 Mechanism of Action Setmelanotide is an MC4 receptor agonist with 20-fold less activity at the melanocortin 3 (MC3) and melanocortin 1 (MC1) receptors. MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. Based on nonclinical evidence, setmelanotide may re establish MC4 receptor pathway activity to reduce food intake and promote weight loss through decreased caloric intake and increased energy expenditure in patients with obesity due to acquired HO, BBS, or POMC, PCSK1, or LEPR deficiency associated with insufficient activation of the MC4 receptor. The MC1 receptor is expressed on melanocytes, and activation of this receptor leads to accumulation of melanin and increased skin pigmentation independently of ultraviolet light [see Warnings and Precautions (5.4) and Adverse Reactions (6.1)].

indication

Obesity

phase

marketed

setmelanotide

indications

all catalysts(6)

News(0)

Report a data issue

comments(0)

Patent cliff

patents (3)

FDA exclusivities (5)

🐶 often sniffed alongside

Trials studying setmelanotide